Neoprobe to Present at Wall Street Analyst Forum; CFO To Provide Business Update.

DUBLIN, Ohio -- Please replace the release dated September 21, 2006 with the following corrected version due to multiple revisions to the headline and text.

The corrected release reads:

NEOPROBE TO PRESENT AT WALL STREET ANALYST FORUM; CFO TO PROVIDE BUSINESS UPDATE

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its Vice President, Finance and Chief Financial Officer, Brent Larson, will present tomorrow, September 28, 2006 at 11:10 a.m. EDT, during the 17th Annual Wall Street Analyst Forum to be held at the Princeton Club in New York, NY.

Interested parties can access a live, or archived, internet broadcast of the presentation at:

http://www.investorcalendar.com/CEPage.asp?ID=108415

The presentation will be archived for 30 days.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000[R] line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix([R]) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[R] and RIGScan([R]) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com